Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Can Fite BioPharma Ltd | CANF | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.97 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.97 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.66 - 3.33 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.97 | USD |
Can Fite BioPharma Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 1.50B | - | 743k | -7.63M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Can Fite BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CANF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.25 | 2.34 | 1.94 | 2.02 | 17,702 | -0.28 | -12.44% |
| 1 Month | 2.19 | 2.71 | 1.94 | 2.23 | 20,114 | -0.22 | -10.05% |
| 3 Months | 1.94 | 2.71 | 1.94 | 2.14 | 21,043 | 0.03 | 1.55% |
| 6 Months | 2.17 | 2.80 | 1.81 | 2.14 | 59,085 | -0.20 | -9.22% |
| 1 Year | 1.80 | 3.33 | 1.66 | 2.22 | 40,969 | 0.17 | 9.44% |
| 3 Years | 21.70 | 26.20 | 1.52 | 17.21 | 464,172 | -19.73 | -90.92% |
| 5 Years | 5.10 | 88.765 | 1.52 | 21.45 | 722,568 | -3.13 | -61.37% |
Can Fite BioPharma Description
| Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). |
